Urgent action needed to avoid widespread shortage of in-vitro diagnostic tests

In a new statement, BioMed Alliance highlights its increasing concern about the availability of In Vitro Diagnostic (IVD) testing devices in Europe.

EU calls for proposal 2023

IntroductionHorizon Europe is the research and innovation programme of the EU for the period 2021-2027. The programme facilitates research collaboration and strengthens the impact of R&I in developing, supporting and implementing EU policies while tackling global challenges.

EHA Research Mobility Grants

The call for applications is now open

EHA strives to develop the career of young scientists by supporting mobility and facilitating a visit to a research group in another institute.

Call for interest — EHA Exam Question Writers Group

The call for interest closed on October 7, 2024. EHA would like to appoint four new members of the European Hematology Exam Question Writers Group.

EHA and EBMT joint meeting on CAR T cells, first of its kind in Europe

The European Hematology Association (EHA) and European Society for Blood and Marrow Transplantation (EBMT) will hold the first European CAR T Cell Meeting together in Paris on February 14-16, 2019.

Publications

Balduini C, Freson K, Greinacher A, Gresele P, Kühne T, Scully M, Bakchoul T, Coppo P, Dovc Drnovsek T, Godeau B, Gruel Y, Rao AK, Kremer Hovinga JA, Makris M, Matzdorff A, Mumford A, Pecci A, Raslova H, Rivera J,…

Recommendations for COVID-19

Is TRTH for me?

Please see the eligibility criteria in the dropdown menu below.

Is CRTH for me?

Eligibility
Applicant must be a trainee or junior faculty and hold an MD or MD/PhD 
Applicant must be actively employed in a hematology or hematology-related research environment 
The applicant must be an EHA member or EHA Guest at the time of application submission…

Promising results in trials with non-chemotherapy treatments for Leukemias to be presented at the 18th Congress of the European Hematology Association in Stockholm, June 13-16, 2013

What is new? Current investigations are aimed at evaluating the use of monoclonal antibodies (mAB). These mABs bind to specific molecules (antigens) found on leukemic cells. This results in immune destruction of the leukemic cells.